drugset / Trial / NCT03746652
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 2
Unknown
50 enrolled
Hellenic Society of Hematology
Janssen Pharmaceutica · collabTakeda · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the efficacy of daratumumab in combination with ixazomib and dexamethasone as second line treatment for relapsed Multiple Myeloma patients.
Timeline
- Start
- 2018-12
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |
| Background | Ixazomib | Unknown | 4 mg | Oral |